In a clinical trial, statistical reports are typically concerned about the mean difference in two groups. Now there is increasing interest in the heterogeneity of the treatment effect, which has important implications in treatment evaluation and selection. The treatment harm rate (THR), which is defined by the proportion of people who has a worse outcome on the treatment compared to the control, was used to characterize the heterogeneity. Since THR involves the joint distribution of the two potential outcomes, it cannot be identified without further assumptions even in the randomized trials. We can only derive the simple bounds with the observed data. But the simple bounds are usually too wide. In this paper, we use a secondary outcome that satisfies the monotonicity assumption to tighten the bounds. It is shown that the bounds we derive cannot be wider than the simple bounds. We also construct some simulation studies to assess the performance of our bounds in finite sample. The results show that a secondary outcome, which is more closely related to the primary outcome, can lead to narrower bounds. Finally, we illustrate the application of the proposed bounds in a randomized clinical trial of determining whether the intensive glycemia could reduce the risk of development or progression of diabetic retinopathy.
Biometry Clinical Trials as Topic